Gland Pharma Limited
GLAND
Classement en actions
#3302
Gland Pharma Limited, established in Hyderabad, India, in 1978, is a... Gland Pharma Limited, established in Hyderabad, India, in 1978, is a pharmaceutical company that specializes in the creation, production, and global distribution of generic injectable medications. Its product line features key active pharmaceutical ingredients such as heparin sodium, enoxaparin sodium, rocuronium bromide, and daptomycin injections, among others. The company's extensive therapeutic portfolio encompasses anti-infectives, anesthetics, anticoagulants, antimalarials, cardiovascular drugs, gastrointestinal treatments, pain management, hormones, fertility aids, anti-cancer agents, gynecological remedies, neurological and central nervous system medications, respiratory treatments, blood-related products, ophthalmological and otological solutions, orthopedics, hematinics, and various vitamins, minerals, and nutrients. Additionally, Gland Pharma provides contract development services. The company primarily operates on a business-to-business (B2B) model, distributing its products across major markets including the United States, Europe, Canada, Australia, India, and other international territories. Gland Pharma Limited functions as a subsidiary of Fosun Pharma Industrial Pte. Ltd.
Prix de l'action
$32.32
Capitalisation boursière
$5.33B
Changement (1 jour)
-3.01%
Changement (1 an)
47.99%
Pays
IN
Échange Gland Pharma Limited (GLAND)
Catégorie
Healthcare
Bénéfices pour Gland Pharma Limited (GLAND)
Bénéfices en Jun 2026 TTM : $175.12M
Selon les derniers rapports financiers de Gland Pharma Limited, les bénéfices actuels de l'entreprise sont de $175.12M. En 2024, l'entreprise a réalisé un bénéfice de $135.82M, une augmentation par rapport à celui de 2023 qui était de $128.32M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Gland Pharma Limited de 2017 à 2026
Bénéfices à la fin de chaque année
| Année | Bénéfices | Changez |
|---|---|---|
| 2026 (TTM) | $175.12M | 40.94% |
| 2025 | $124.25M | -8.52% |
| 2024 | $135.82M | 5.84% |
| 2023 | $128.32M | -39.82% |
| 2022 | $213.22M | 16.94% |
| 2021 | $182.34M | 38.35% |
| 2020 | $131.79M | 33.35% |
| 2019 | $98.83M | 28.32% |
| 2018 | $77.02M | -13.59% |
| 2017 | $89.13M | 0.00% |
Bénéfices des entreprises similaires ou concurrentes
| Entreprise | Bénéfices | Différence de bénéfices | Pays |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 907.63% |
IN
|
